Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

Zhihong Zeng, MD, Rui-Yu Wang, MD PhD, Yuexi Shi, MD, Yihua Qiu, MD, Duncan H Mak, MS, Kevin Coombes, PhD, Suk Young Yoo, PhD, Katti Jessen, Yi Liu, PhD, Christian Rommel, PhD, Hagop M. Kantarjian, MD, Steven M. Kornblau, MD, David Fruman, PhD, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 3613.

https://doi.org/10.1182/blood.V124.21.3613.3613

Published: 2014

Journal Articles

MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

Irene M. Ghobrial, MD, David Siegel, MD, PhD, Ravi Vij, MD, Jeffrey L Wolf, MD, Jesus G. Berdeja, MD, Jeffrey V. Matous, MD, Peter Lipman, PhD, Chirag Patel, MS, PhD, Trinh Le, Christian Rommel, PhD, Gregory Berk, MD

Blood (2012) 120 (21): 4038.

https://doi.org/10.1182/blood.V120.21.4038.4038

Published: 2012

Journal Articles

The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models

David A Fruman, PhD, Matthew Robert Janes, MPH, Sharmila Mallya, MS, Collin C Vu, MD, Marie P. Shieh, MD, Michael B. Lilly, MD, Leonard S Sender, MD, Michael B Martin, PhD, Pingda Ren, PhD, Yi Liu, PhD, Christian Rommel, PhD

Blood (2011) 118 (21): 2585.

https://doi.org/10.1182/blood.V118.21.2585.2585

Published: 2011

Journal Articles

Role of TORC1 and TORC2 in Multiple Myeloma

Patricia Maiso, PhD, Yi Liu, PhD, Abdel Kareem Azab, PhD, BSPharm, Brittany Morgan, Feda Azab, BPharm, Antonio Sacco, BS, Michaela Reagan, PhD, Hai T Ngo, BS, Yang Liu, PhD, Yong Zhang, PhD, Charles Lin, PhD, Aldo M Roccaro, MD, PhD, Christian Rommel, PhD, Irene M. Ghobrial, MD

Blood (2011) 118 (21): 1815.

https://doi.org/10.1182/blood.V118.21.1815.1815

Published: 2011

Journal Articles

Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma

Patricia Maiso, PhD, AbdelKareem Azab, PhD, Yang Liu, PhD, Yong Zhang, PhD, Feda Azab, Antonio Sacco, Hai T Ngo, Yi Liu, PhD, Brittany Morgan, Christian Rommel, PhD, Kenneth C. Anderson, MD, Aldo M. Roccaro, MD, PhD, Irene M. Ghobrial, MD

Blood (2010) 116 (21): 133.

https://doi.org/10.1182/blood.V116.21.133.133

Published: 2010

Journal Articles

Targeting mTORC1/2 by a mTOR Kinase Inhibitor (PP242) induces Apoptosis In AML Cells Under Conditions Mimicking Bone Marrow Microenvironment

Zhihong Zeng, Yuexi Shi, Twee Tsao, Yihua Qiu, Steven M. Kornblau, MD, Keith Baggerly, Wenbin Liu, Yi Liu, PhD, Christian Rommel, PhD, David A. Fruman, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD

Blood (2010) 116 (21): 778.

https://doi.org/10.1182/blood.V116.21.778.778

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models

Role of TORC1 and TORC2 in Multiple Myeloma

Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma

Targeting mTORC1/2 by a mTOR Kinase Inhibitor (PP242) induces Apoptosis In AML Cells Under Conditions Mimicking Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Update search

MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models

Role of TORC1 and TORC2 in Multiple Myeloma

Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma

Targeting mTORC1/2 by a mTOR Kinase Inhibitor (PP242) induces Apoptosis In AML Cells Under Conditions Mimicking Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only